Gland Pharma has signed a deal with the Russian Direct Investment Fund (RDIF) to make up to 252 million doses of the Sputnik V COVID-19 vaccine, bringing India’s total production of the shot to at least 352 million.

India’s Hetero already has a deal in place to produce over 100 million doses of the vaccine, which has proven to be 91.6 per cent effective against COVID-19.

Sputnik V, developed by Moscow’s Gamaleya Institute, has been approved in 22 countries, with the RDIF signing supply deals with over 13 countries.

Dr Reddy’s Laboratories has also been holding small clinical studies of Sputnik V domestically. It had sought emergency use approval for the vaccine last month, but India’s drug regulator had asked for more data.

Production is expected to begin in the third quarter at its facilities in Hyderabad, with deliveries estimated in the final quarter of the year, Gland Pharma said in a statement. It did not specify which countries it would supply the doses to.

Gland Pharma also said it would explore more deals for the vaccine.